Home / Fact sheets / Rwanda / Cervical qualitative data

Country fact sheet: Rwanda

CERVICAL CANCER SCREENING PROGRAMME

Reporting year for qualitative data: 2020
Source of qualitative data: Directly from Programme

There is a pilot project:
  • Starting year: 2020
  • Ending year: no information
  • Primary test: HPV DNA testing, VIA is used as the triage method
  • Sample size: no information
  • Location: no information

Organization of screening

An individual/team/institution responsible to coordinate the programme: Yes
Dedicated budget for screening programme: Yes
Documented cancer screening policy: Yes
Nature of documentation of the policy: Notification
Year programme was initiated: 2013
Programme introduction was preceded by a pilot: No
Screening tests provided free of charge: Yes
Diagnostic tests provided free of charge: No
Treatment services provided free of charge: No

Information system and data collection

System that collects data: Individual & Aggregated
   • Identification of eligible population: No
   • Screening participation: Aggregated
   • Screening test results: Individual & Aggregated
   • Further assessment: No
   • Final pathology diagnosis: Individual & Aggregated
   • Cancer staging: No
   • Treatment: Individual & Aggregated
The information system exists at national or sub-national level: Individual: Sub-national
Aggregated: National
The information system collects data outside the programme (opportunistic screening/private sector): Yes
Cancer screening data is linked with population-based cancer registry (PBCR): No

Screening protocol

A screening protocol or guideline: Yes
Year of published/updated protocol: 2020
Target age (min-max) and screening interval [months] for each test: HPV (30-49 years / [36 months])
VIA (30-49 years / [36 months])
Triaging test used: VIA
Self-collection HPV recommended: No
"Screen and treat" included in the protocol: Yes
Treatment modality for "screen and treat": Thermal ablation
LLETZ/CKC

Invitations for screening and further assessment

Initiatives to create population awareness by the Health Ministry/Health Authority: Mass media campaign
Small media campaign
Group education
One-on-one education
Dedicated website
Invitations to eligible population: No
Source of the eligible individuals identified: -
Method of invitation: -
Screening kit included with the invitation: -
Screen positive individuals actively contacted for further assessment: Yes
Individuals with a precancer or cancer diagnosis actively contacted: Yes

Quality Assurance (QA) of screening activities

Documented standard operating procedure/policy for QA: No
An individual/team/institution responsible for QA: Yes
Accreditation of lab services: Yes
Accreditation of pathology services: No
Documented performance indicators: No
Reference standards for performance indicators: -
Evaluation reports published in the last five years: No

Performance indicators

Reporting year for quantitative data: 2020
Source of quantitative data: Pilot project
Age range and regional limitation if applicable: 30-49 years
Invitation coverage (%):
Participation rate (%):
Examination coverage (%): 21.6
Completeness of data related to screening test results (%): 92.7
Completeness of data related to further assessment results (%):
Further assessment (Colposcopy referral) rate (%):
Further assessment participation rate (%):
Detection rate for CIN2+ (x 1000):
Detection rate for CIN3+ (x 1000):
Detection rate for invasive cancer (x 1000): 0.8
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):
Positive Predictive Value for CIN3+ (x 1000):
Positive Predictive Value for invasive cancer (x 1000):
More quantitative data for a pilot project (2020/HPV)


Check also the following factsheets: Rwanda, Breast, Colorectal